NEW YORK (TheStreet) -- Shares of MiMedx (MDXG) fell 18.65% to $9.38 in morning trading Friday after the company announced late Wednesday it had received a subpoena from U.S. regulators.
The company, which specializes in regenerative medicine, said it received a subpoena from the Office of the Inspector General of the Department of Health and Human Services in connection with a civil investigation mostly tied to the company's sales and marketing activities.
Separately, MiMedx announced late Wednesday it had filed a federal tortious interference lawsuit against Organogenesis, the manufacturer of Apligraf and Dermagraft, two skin substitute products that compete with MiMedx's EpiFix allograft. MiMedx alleged that Organogenesis interfered with MiMedx's dealings with the Veterans Administration.
The company, which specializes in regenerative medicine, said it received a subpoena from the Office of the Inspector General of the Department of Health and Human Services in connection with a civil investigation mostly tied to the company's sales and marketing activities.
Separately, MiMedx announced late Wednesday it had filed a federal tortious interference lawsuit against Organogenesis, the manufacturer of Apligraf and Dermagraft, two skin substitute products that compete with MiMedx's EpiFix allograft. MiMedx alleged that Organogenesis interfered with MiMedx's dealings with the Veterans Administration.
OIG Investigation
Aucun commentaire:
Enregistrer un commentaire